Published March 30, 2022 | Version v1
Journal article Open

Real-World Walking Speed Assessment Using a Mass-Market RTK-GNSS Receiver

  • 1. Health Sciences and Technologies-Interdepartmental Center for Industrial Research (CIRI-SDV), University of Bologna, Bologna, Italy
  • 2. Health Sciences and Technologies-Interdepartmental Center for Industrial Research (CIRI-SDV), University of Bologna, Bologna, Italy. Department of Electrical, Electronic, and Information Engineering "Guglielmo Marconi", University of Bologna, Bologna, Italy

Description

Walking speed is an important clinical parameter because it sums up the ability to move and predicts adverse outcomes. However, usually measured inside the clinics, it can suffer from poor ecological validity. Wearable devices such as global positioning systems (GPS) can be used to measure real-world walking speed. Still, the accuracy of GPS systems decreases in environments with poor sky visibility. This work tests a solution based on a mass-market, real-time kinematic receiver (RTK), overcoming such limitations. Seven participants walked a predefined path composed of tracts with different sky visibility. The walking speed was calculated by the RTK and compared with a reference value calculated using an odometer and a stopwatch. Despite tracts with totally obstructed visibility, the correlation between the receiver and the reference system was high (0.82 considering all tracts and 0.93 considering high-quality tracts). Similarly, a Bland Altman analysis showed a minimal detectable change of 0.12 m/s in the general case and 0.07 m/s considering only high-quality tracts. This work demonstrates the feasibility and validity of the presented device for the measurement of real-world walking speed, even in tracts with high interference. These findings pave the way for clinical use of the proposed device to measure walking speed in the real world, thus enabling digital remote monitoring of locomotor function. Several populations may benefit from similar devices, including older people at a high risk of fall, people with neurological diseases, and people following a rehabilitation intervention.

Notes

The MOBILISE-D project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No. 820820. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation program and the European Federation of Pharmaceutical Industries and Associations (EFPIA).

Files

2022_Reggi_30032022.pdf

Files (2.3 MB)

Name Size Download all
md5:0490720590b5b8695db0001a163b1a9c
2.3 MB Preview Download

Additional details

Funding

European Commission
MOBILISE-D - Connecting digital mobility assessment to clinical outcomes for regulatory and clinical endorsement 820820